DexCom (NASDAQ:DXCM) Rating Lowered to Hold at StockNews.com

DexCom (NASDAQ:DXCM) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other equities analysts also recently issued reports on DXCM. Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Trading Up 1.9 %

DexCom stock traded up $2.48 during mid-day trading on Tuesday, hitting $134.00. The company’s stock had a trading volume of 2,014,507 shares, compared to its average volume of 2,958,850. The company has a 50 day moving average of $130.15 and a 200-day moving average of $117.74. The stock has a market cap of $51.66 billion, a PE ratio of 102.29, a P/E/G ratio of 2.25 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. DexCom’s quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 EPS. On average, research analysts anticipate that DexCom will post 1.76 EPS for the current year.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 in the last three months. 0.41% of the stock is owned by insiders.

Institutional Trading of DexCom

Hedge funds and other institutional investors have recently bought and sold shares of the stock. LaFleur & Godfrey LLC grew its holdings in DexCom by 19.0% in the first quarter. LaFleur & Godfrey LLC now owns 4,983 shares of the medical device company’s stock valued at $691,000 after purchasing an additional 797 shares during the period. Oak Harbor Wealth Partners LLC acquired a new stake in DexCom in the first quarter valued at approximately $200,000. Gradient Investments LLC grew its holdings in DexCom by 4.6% in the first quarter. Gradient Investments LLC now owns 159,841 shares of the medical device company’s stock valued at $22,170,000 after purchasing an additional 7,002 shares during the period. Fifth Third Bancorp grew its holdings in DexCom by 20.4% in the first quarter. Fifth Third Bancorp now owns 30,605 shares of the medical device company’s stock valued at $4,245,000 after purchasing an additional 5,176 shares during the period. Finally, Summit Trail Advisors LLC grew its holdings in DexCom by 30.6% in the first quarter. Summit Trail Advisors LLC now owns 3,188 shares of the medical device company’s stock valued at $442,000 after purchasing an additional 747 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.